Novel approaches in allogeneic stem cell transplantation
- PMID: 16901394
- DOI: 10.1007/s11912-006-0054-0
Novel approaches in allogeneic stem cell transplantation
Abstract
Allogeneic transplantation remains an integral part of the management of hematologic malignancies. However, transplant-related mortality, graft-versus-host disease, and disease recurrence continue to be major limitations to successful transplant outcomes and challenges to investigators in the field. Newer approaches have focused on reduction of the intensity of the conditioning regimens, harnessing the antitumor effects of the allograft, and development of adoptive immunotherapy strategies to circumvent the limitations. These developments provide physicians with the ability to tailor transplants to specific patients and their diseases.
Similar articles
-
Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.Expert Rev Hematol. 2010 Jun;3(3):301-14. doi: 10.1586/ehm.10.29. Expert Rev Hematol. 2010. PMID: 21082981 Review.
-
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.Biol Blood Marrow Transplant. 2006 Aug;12(8):868-75. doi: 10.1016/j.bbmt.2006.05.006. Biol Blood Marrow Transplant. 2006. PMID: 16864057 Clinical Trial.
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Adoptive allogeneic immunotherapy--history and future perspectives.Transfus Sci. 2000 Oct;23(2):133-50. doi: 10.1016/s0955-3886(00)00078-3. Transfus Sci. 2000. PMID: 11035275 Review.
-
Do different conditioning regimens really make a difference?Hematology Am Soc Hematol Educ Program. 2012;2012:237-45. doi: 10.1182/asheducation-2012.1.237. Hematology Am Soc Hematol Educ Program. 2012. PMID: 23233587 Review.
Cited by
-
The symptom experience in the first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT).Support Care Cancer. 2008 Nov;16(11):1243-54. doi: 10.1007/s00520-008-0420-6. Epub 2008 Mar 6. Support Care Cancer. 2008. PMID: 18322708 Free PMC article.